All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

HARMONIC Evaluates Novel Combination in Growing Population of Never Smokers With Advanced Lung Cancer

November 22nd 2022

In combination with standard-of-care carboplatin and pemetrexed, the investigational agent LP-300 will be evaluated in never smokers with non–small cell lung cancer in the phase 2 HARMONIC study.

Precision Medicine Provides Continued Benefit in mCRPC

November 21st 2022

Daniel J. George, MD, discusses the clinical implications use of key trials in metastatic castration-resistant prostate cancer.

Zandelisib Elicits High Response Rates in Indolent Non-Hodgkin Lymphoma

November 21st 2022

The oral PI3Kδ inhibitor zandelisib produced an overall response rate in Japanese patients with relapsed/refractory indolent B-cell non-Hodgkin lymphoma without small lymphocytic lymphoma, lymphoplasmacytic lymphoma, and Waldenström macroglobulinemia.

Advances in Breast Cancer Treatment Reshape Treatment Paradigms in 2022

November 21st 2022

The increasing role of antibody-drug conjugates have led to questions of sequencing for patients with HER2-positive breast cancer, whereas new data for first-generation PD-L1 inhibitors, such as pembrolizumab have shaken up the treatment paradigm for others.

How Bacteria Give Cancer a Helping Hand

November 21st 2022

Two new studies show how bugs could help tumors progress and resist treatment.

FDA Grants Priority Review to Epcoritamab for Relapsed/Refractory LBCL

November 21st 2022

The FDA has accepted and granted priority review to a biologics license application seeking the apporoval of epcoritamab in patients with relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic therapy.

Tumor Profiling Studies Illuminate Nuances Across Malignancies

November 21st 2022

Molecular and immune landscapes for solid tumors are constantly evolving as precision medicine techniques become more sensitive and next-generation sequencing methods are taken up in clinical practice.

Iovance to Address FDA Requests for BLA of Lifileucel in Advanced Melanoma

November 21st 2022

After receiving FDA feedback regarding supplemental assay validation information and comparability data for lifileucel in advanced melanoma, Iovance Biotherapeutics will address these comments and plans to complete its rolling biologics license application submission during the first quarter of 2023.

Quality Improvement Project Shows Reduced Time From Diagnosis to NGS in Patients With NSCLC

November 21st 2022

The median time between pathologic diagnosis to next-generation sequencing was reduced in a quality improvement project for patients with newly diagnosed metastatic non–small cell lung cancer.

Advanced Prostate Cancer Treatment Benefits From Updated Guidelines and Adaptive Sequencing Strategies

November 19th 2022

Treatment developments in advanced prostate cancer are hinging on the benefits of triplet therapy and individualized care, the results of which are also informing treatment sequencing.

FDA Approves Additional Dosing Schedule for Rylaze in ALL and LBL

November 18th 2022

The FDA has approved a supplemental biologics license application to add a Monday/Wednesday/Friday intramuscular dosing schedule for asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze).

Luminary Awards Honor GI Experts, Patient Advocate

November 18th 2022

OncLive® and The Ruesch Center for the Cure of Gastrointestinal Cancers at Georgetown Lombardi Comprehensive Cancer Center, have recognized 4 gastrointestinal physician-scientists and a prominent patient advocate, naming them as 2022 Luminary Awards in GI Cancers.

European Commission Approves Zanubrutinib for CLL

November 18th 2022

The European Commission has approved zanubrutinib for the treatment of adult patients with treatment-naïve or relapsed/refractory chronic lymphocytic leukemia.

Camsirubicin Elicits Early Clinical Activity in Advanced Soft Tissue Sarcoma

November 18th 2022

Camsirubicin in combination with pegfilgrastim produced encouraging clinical activity and safety in patients with advanced soft tissue sarcoma.

FDA Seeks to Restrict Rucaparib to Second-line Maintenance Therapy in Recurrent Ovarian Cancer

November 18th 2022

The FDA has asked Clovis Oncology to limit use of rucaparib to second-line maintenance therapy for patients with recurrent ovarian cancer harboring BRCA mutations.

DCVax-L Improves Survival in Glioblastoma

November 18th 2022

Autologous tumor lysate-loaded dendritic cell vaccination used in combination with standard-of-care treatment extended overall survival for patients with newly diagnosed glioblastoma as well as those with recurrent disease.

BTK Inhibitor Failure Signals Unmet Need for a Standard of Care in Relapsed/Refractory MCL

November 18th 2022

Improved mantle cell lymphoma treatments are necessary for patients who have relapsed on or are refractory to BTK inhibitors, according to findings from SCHOLAR-2, a multicenter, retrospective chart review of European patients with MCL who relapsed following or were intolerant to BTK inhibitors.

Ponatinib Provides Higher Rate of MRD-negative CR Vs Imatinib in Newly Diagnosed Ph+ ALL

November 17th 2022

Ponatinib plus reduced-intensity chemotherapy produced a higher rate of minimal residual disease–negative complete remission compared with imatinib in patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia.

Ibrutinib Demonstrates Real-world ORR Benefit in Relapsed/Refractory MCL

November 17th 2022

Ibrutinib therapy remains an effective treatment, particularly in the second line, in patients with relapsed/refractory mantle cell lymphoma.

Hackensack Meridian Health Appoints Internationally Renowned Thoracic Surgeon Faiz Y. Bhora, MD, FACS, as Central Region Chair of Surgery

November 17th 2022

Expert in minimally invasive and robotic surgery will expand access to new technology and advancesurgical research in Central New Jersey.